Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Sharp and Dohme and Samsung Bioepis announce biosimilar alliance

Merck Sharp and Dohme and Samsung Bioepis announce biosimilar alliance

21st February 2013

Merck Sharp and Dohme has entered into a new agreement with Samsung Bioepis on the creation of new biosimilar therapies against a number of clinical targets.

The agreement will see Samsung Bioepis take responsibility for preclinical, clinical and process development, manufacturing, clinical trials and registration for the therapies, while Merck will be in charge of commercialisation.

Samsung Bioepis will receive an upfront payment and product supply income from its partner, as well as additional payments associated with pre-specified clinical and regulatory milestones.

This will help Samsung to improve its standing in the pharmaceutical industry, while complementing Merck's expanding internal biologics portfolio.

Dr Rich Murray, senior vice-president for biologics and vaccines research at Merck Research Laboratories, said: "The combination of Merck's global commercial presence with Samsung Bioepis' biologic development and manufacturing capabilities positions the two companies well to increase access to biosimilars to improve human health."

This comes after the company highlighted the pursuit of "external opportunities" as one of its key growth strategies for 2013 in its most recent financial report, which was released earlier this month.ADNFCR-8000103-ID-801544156-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.